Farxiga(Dapagliflozin Propanediol)
AZN
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AstraZeneca PLC
$5.29B
Medicare cost, 2024
$5.29B
Medicare cost, 2024
Medicare drug plans spent $5.3 billion on Farxiga (dapagliflozin propanediol) in 2024, for 5.6 million prescriptions and refills filled by 1.3 million patients. It ranks 8th among all drugs by Medicare drug plan spending. Spending rose 22% from 2023 to 2024. Texas accounts for the most spending ($470.4 million, 9% of the total).
Medicare cost, 2024
$5.29B
+21.8% from 2023
Prescriptions
5.6M
$938.93 per claim
Patients
1.3M
266,350 prescribers
Total spending, 2024
$5.29B
$4,168.36 per patient
Questions and answers
How much does Medicare spend on Farxiga?
Medicare prescription drug plans paid $5.29B for Farxiga in 2024, for 5,632,811 prescriptions and refills to 1,268,791 patients (up 21.8% from 2023). The average cost per claim was $938.93.
Which state spends the most on Farxiga?
Texas had the highest Medicare cost for Farxiga in 2024: $470.4M for 474,557 claims, followed by California ($450.5M).
Who prescribes Farxiga the most?
Wei Y Sun, nephrology in New York, NY, had the highest Medicare cost for Farxiga in 2024: 3,361 claims costing $2.2M.
Who makes Farxiga?
Farxiga is made by AstraZeneca PLC (AZN), listed in the Medicare spending data as Astrazeneca.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Farxiga was $5.29B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Farxiga, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Wei Y Sun New York, NY | Nephrology | 3,361 | 561 | $2.2M |
| Mohammad A Chaudhry Union City, NJ | Internal Medicine | 1,822 | 436 | $1.9M |
| Carlos R Figueroa Nunez San Juan, PR | Endocrinology | 2,106 | 401 | $1.4M |
| Francisco Pons Miami, FL | Internal Medicine | 1,968 | 457 | $1.3M |
| Ankush Gulati Lehigh Acres, FL | Nephrology | 1,028 | 321 | $1.3M |
| Minesh Rajpal Peoria, AZ | Nephrology | 1,068 | 270 | $1.2M |
| Manavendra Bakhshi Philadelphia, PA | Cardiology | 1,629 | 309 | $1.2M |
| Luis R Garcia-Mayol Coral Gables, FL | Nephrology | 1,429 | 303 | $1.2M |
| Paul-Moreau Bossous Mission, TX | Nephrology | 1,139 | 374 | $1.2M |
| Nhan T Luu Galion, OH | Nephrology | 1,006 | 285 | $1.2M |
| 1710074026 | Internal Medicine | 1,184 | 235 | $1.2M |
| Najmuddin K Karimjee Houston, TX | Internal Medicine | 1,073 | 358 | $1.1M |
| Carlos M Martinez Rivera Mayaguez, PR | Endocrinology | 1,548 | 310 | $1.1M |
| Eddie M Rodriguez-Castro Bayamon, PR | Nephrology | 903 | 293 | $1.1M |
| Ahed Mansoura Rome, GA | Endocrinology | 873 | 225 | $1.1M |
| Michael M Dao Garden Grove, CA | Internal Medicine | 1,002 | 257 | $1.0M |
| Eliscer Guzman New York, NY | Internal Medicine | 1,056 | 297 | $1.0M |
| Henry C Yee Alhambra, CA | Cardiology | 1,243 | 292 | $1.0M |
| Elizabeth Liang Flushing, NY | Nephrology | 1,509 | 263 | $996K |
| Glenn H Herrington Wilmington, NC | Pharmacist | 645 | 216 | $985K |
| Jose R Baez Lawrence, MA | Internal Medicine | 1,472 | 248 | $948K |
| Denise Caro Mayaguez, PR | Endocrinology | 1,302 | 234 | $941K |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 1,165 | 234 | $910K |
| Maritza Melendez Nieves Fajardo, PR | Internal Medicine | 617 | 185 | $900K |
| Lisa O Cabrera San Antonio, TX | Nephrology | 1,153 | 271 | $896K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 178,604 | 2,664,228 | 638,606 | $2.58B |
| 2023 | 230,477 | 4,296,969 | 993,405 | $4.34B |
| 2024 | 266,350 | 5,632,811 | 1,268,791 | $5.29B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Astrazeneca | 5,634,650 | $5.29B |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 63,809 side-effect reports named dapagliflozin propanediol, the active ingredient of Farxiga (reports from 2008 on). 49,079 of them (76.9%) were serious, 10,667 named a death and 18,402 named a hospital stay. The reactions named most often were death, nausea and fatigue. 49,388 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
63,809
13,231 in 2025 (+12.5% from 2024)
Serious
76.9%
49,079 reports
Deaths named
10,667
16.7% of reports
Hospital stays
18,402
28.8% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Farxiga?
63,809 reports from 2008 through September 2026 named dapagliflozin propanediol, the active ingredient of Farxiga. 49,079 of them (76.9%) were serious, 10,667 named a death and 18,402 named a hospital stay.
What are the most reported side effects of Farxiga?
8,630 reports named death, the reaction named most often, followed by nausea (2,831) and fatigue (2,810). In the last 5 years the reaction named most often was death (8,302 reports). A report can name several reactions.
How many side-effect reports named Farxiga in 2025?
13,231 reports were received in 2025 (+12.5% from 2024). 2026 so far: 9,970 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Farxiga caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Farxiga caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
AZN·AZN drug pipeline - Drug approvals · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (dapagliflozin propanediol) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.